Trial Profile
A trial to study efficacy and safety of initial combination therapy with gemigliptin and metformin vs. gemigliptin or metformin monotherapy in drug-naïve patients with type 2 diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Jun 2016
Price :
$35
*
At a glance
- Drugs Gemigliptin/metformin (Primary) ; Gemigliptin; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 02 Jun 2016 Primary endpoint (change from baseline in HbA1c after 24 weeks) has been met, according to results presented at The 98th Annual Meeting of the Endocrine Society
- 02 Jun 2016 New trial record
- 04 Apr 2016 Results presented at The 98th Annual Meeting of the Endocrine Society